68Ga-PSMA PET/CT for Ra223 Assessment
Recruiting now · Not applicable
Conditions studied: Metastatic Prostate Cancer
In brief
Primary objective: i.The primary objective is to compare the diagnostic positivity in progression of 68Ga-PSMA PET and Bone scan. Secondary objectives: i.The correlation between PET osseous tumor burden index and Alk-P level ii.The correlation between PET osseous tumor burden index and PSA level
Key facts
- Study ID
- NCT04951817
- Run by
- Chang Gung Memorial Hospital
- People needed
- 52
- Starts
- 2022-03-02
- Expected to finish
- 2025-08-31
- Last updated by the study team
- 2025-08-29
Who can join
Age: 40 and older, up to 85. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Males with 40-85 years of age and life expectancy more than 3 months
- Patient was diagnosed as mCRPC, and meet the standard criteria of using 223Ra-dichloride (symptomatic bone metastasis, at least two bone metastasis sites, no visceral organ metastasis)
- Willing to sign the informed consent
- ECOG performance status Grade 0-2
You may not qualify if…
- Unable to tolerate the PET/CT scan, such as those with claustrophobia, unable to lie still, consciousness unclear, vital sign unstable.
- With renal impairment (glomerular filtration rate lower than 30 ml/min/1.73 m2), and allergy to medium contrast.
- Significant abnormal lab data (AST or ALT more than three times of normal value), and high risk to conduct examination after evaluations of PI.
- Patient had previous other malignancy history
- Patient experiences grade 3-4 neutropenia (neutrophil counts less than 1000/uL) or thrombocytopenia (platelet counts less than 50x103/uL) lasting > 14 days
Where it is running
- Chang Gung Memorial Hospital ,Linkou — Taoyuan City, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.